International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(5), С. 2354 - 2354
Опубликована: Март 6, 2025
In
recent
years,
there
has
been
a
dynamic
development
in
therapies
utilizing
extracellular
vesicles
(EVs)
including
exosomes.
Therefore,
we
have
conducted
an
analysis
of
the
scientific
literature
to
verify
current
state
knowledge
about
these
therapies.
A
total
12
clinical
studies
were
analyzed,
covering
use
EVs
treating
skin
aging,
acne
scars,
alopecia,
and
wound
healing.
The
results
indicate
that
exosomes
hold
potential
regenerative
therapies,
offering
innovative
non-invasive
therapeutic
approaches.
At
same
time,
significant
challenges
related
standardization
their
production
lack
large-scale
randomized
identified.
Thus,
also
evaluated
investigated
trials
regard
MISEV
(Minimal
Information
for
Studies
Extracellular
Vesicles)
criteria.
This
review
provides
comprehensive
overview
contemporary
applications
therapy
medicine,
highlighting
directions
further
research.
ACS Applied Bio Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 12, 2025
As
we
progress
into
the
21st
century,
cancer
stands
as
one
of
most
dreaded
diseases.
With
approximately
in
every
four
individuals
facing
a
lifetime
risk
developing
cancer,
remains
serious
health
challenges
worldwide.
Its
multifaceted
nature
makes
it
an
arduous
and
tricky
problem
to
diagnose
treat.
Over
years,
researchers
have
explored
plenty
approaches
avenues
improve
management.
One
notable
strategy
includes
study
extracellular
vesicles
(EVs)
potential
biomarkers
therapeutics.
Among
these
EVs,
exosomes
emerged
particularly
promising
candidates
due
their
unique
characteristic
properties
functions.
They
are
small
membrane-bound
secreted
by
cells
carrying
cargo
biomolecules
such
proteins,
nucleic
acids,
lipids.
These
play
crucial
roles
intercellular
communication,
facilitating
transfer
biological
information
between
cell-to-cell
communication.
Exosomes
transport
cargoes
DNA,
RNA,
lipids
involved
cellular
reprogramming
promoting
cancer.
In
this
review,
explore
molecular
composition
exosomes,
significance
chemistry
development,
its
theranostic
application
well
research
complications
solutions.
Theranostics,
Год журнала:
2024,
Номер
14(5), С. 2265 - 2289
Опубликована: Янв. 1, 2024
Extracellular
vesicles
(EVs)
are
produced
by
all
cells
in
the
body.
These
biological
nanoparticles
facilitate
cellular
communication
through
transport
of
diverse
cargoes,
including
small
molecules,
proteins,
and
nucleic
acids.
mRNA
cargoes
have
gained
particular
interest
given
their
role
translation
functional
proteins.
As
a
biomarker
platform,
EVs
can
be
found
nearly
biofluids-blood,
mucus,
urine,
cerebrospinal
fluid,
saliva-providing
real-time
insight
into
parent
cell
tissue
function.
mRNAs
carried
protected
from
degradation,
resulting
improved
detection
compared
to
free
mRNA,
recent
work
demonstrates
promising
results
using
these
as
biomarkers
for
cancer,
neurological
diseases,
infectious
gynecologic
obstetric
outcomes.
Furthermore,
innate
cargo
carrying,
targeting,
barrier
crossing
abilities
EVs,
structures
been
proposed
therapeutic
carriers
mRNA.
Recent
advances
demonstrate
methods
loading
range
disease
indications.
Here,
we
review
studies
diagnostics
therapeutics.
We
discuss
challenges
associated
with
diagnostic
applications
highlight
opportunities
future
development.
Nano Letters,
Год журнала:
2023,
Номер
24(1), С. 1 - 8
Опубликована: Дек. 20, 2023
Extracellular
vesicles
and
lipoproteins
are
lipid-based
biological
nanoparticles
that
play
important
roles
in
(patho)physiology.
Recent
evidence
suggests
extracellular
can
interact
to
form
functional
complexes.
Such
complexes
have
been
observed
biofluids
from
healthy
human
donors
various
vitro
disease
models
such
as
breast
cancer
hepatitis
C
infection.
Lipoprotein
components
also
part
of
the
biomolecular
corona
surrounds
contributes
identity.
Potential
mechanisms
relevance
vesicle–lipoprotein
remain
poorly
understood.
This
Review
addresses
current
knowledge
interface
while
drawing
on
pre-existing
liposome
interactions
with
nanoparticles.
There
is
an
urgent
need
for
further
research
lipoprotein–extracellular
vesicle
interface,
which
could
return
mechanistic,
therapeutic,
diagnostic
findings.
ACS Nano,
Год журнала:
2024,
Номер
18(36), С. 24622 - 24649
Опубликована: Авг. 26, 2024
Biobased
therapy
represents
a
promising
strategy
for
myocardial
repair.
However,
the
limitations
of
using
live
cells,
including
risk
immunogenicity
allogeneic
cells
and
inconsistent
therapeutic
efficacy
autologous
together
with
low
stability,
result
in
an
unsatisfactory
clinical
outcomes.
Therefore,
cell-free
strategies
cardiac
tissue
repair
have
been
proposed
as
alternative
strategies.
Cell-free
strategies,
primarily
based
on
paracrine
effects
cellular
therapy,
demonstrated
their
potential
to
inhibit
apoptosis,
reduce
inflammation,
promote
on-site
cell
migration
proliferation,
well
angiogenesis,
after
infarction
explored
preclinically
clinically.
Among
various
modalities,
bioderived
nanoparticles,
adeno-associated
virus
(AAV),
extracellular
vesicles,
membrane-coated
exosome-mimetic
nanovesicles,
emerged
due
improved
biological
function
effect.
The
main
focus
this
review
is
development
existing
nanoparticles
fundamental
working
mechanisms,
challenges
opportunities.
key
processes
requirements
are
summarized
first.
Various
nanoparticle
modalities
further
highlighted,
advantages
limitations.
Finally,
we
discuss
delivery
approaches
that
offer
pathways
researchers
clinicians
translate
into
practice.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(19), С. 10401 - 10401
Опубликована: Сен. 27, 2024
Extracellular
vesicles
(EVs)
are
natural
carriers
of
biomolecules
that
play
a
crucial
role
in
cell-to-cell
communication
and
tissue
homeostasis
under
normal
pathological
conditions,
including
inflammatory
diseases
cancer.
Since
the
discovery
pro-regenerative
immune-modulating
properties
EVs,
EV-based
therapeutics
have
entered
clinical
trials
for
conditions
such
as
myocardial
infarction
autoimmune
diseases,
among
others.
Due
to
their
unique
advantages—such
superior
bioavailability,
substantial
packaging
capacity,
ability
traverse
biological
barriers—EVs
regarded
promising
platform
targeted
drug
delivery.
However,
achieving
sufficient
accumulation
therapeutic
agents
at
target
site
necessitates
larger
quantity
EVs
per
dose
compared
using
standalone
drugs.
This
challenge
can
be
addressed
by
administering
doses
increasing
dosage
administration,
or
enhancing
selective
cells.
In
this
review,
we
will
discuss
methods
improve
isolation
purification
approaches
enhance
cargo
packaging—including
proteins,
RNAs,
small-molecule
drugs—and
technologies
displaying
targeting
ligands
on
surface
facilitate
improved
targeting.
Ultimately,
guide
applied
development
novel
classes
overcoming
existing
technological
challenges.
